GaDia SA
GaDia is developing IVD tests for nosocomial diseases
GaDia reinventes the diagnostic of life-threatening diseases to quickly provide the right information to Health Care professionals
If you are admitted to a hospital you have 10% risk of contracting a Healthcare-acquired infection (nosocomial disease) (WHO 2011).
Sepsis is the major complications of nosocomial diseases and is the first cause of death in the World. Moreover, existing procedures take too much time.
GaDia SA is a Swiss startup developing innovative, patented rapid in vitro diagnostic (IVD) tests to screen nosocomial diseases.
A simple way to save 8 millions lives a year!
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
09.05.2025
Fast growing GaDia wins milestone Tender in Italy (startupticker.ch)
13.10.2021
Startup Challenge IFASinnovation gibt Finalisten bekannt (startupticker.ch)
25.06.2020
Swiss Medtech Award presents the shortlist (startupticker.ch)
08.04.2020
Launch of the first rapid test for COVID-19 on the Swiss market (startupticker.ch)
15.07.2021
Top 25 Startup IFAS Innovation Challenge 2021
15.06.2021
Top 20 Tech Startup for Impact SEIF Award 2021
11.05.2021
Top 100 start-up Swiss Innovation Challenge 2021
01.03.2021
GaDia start a Serie A Fundraising round
No Jobs
Videos
GaDia Prix Créateurs BCVs 2019
GaDia fight Nosocomial diseases
Documents
No Awards
GaDia SA
GaDia is developing IVD tests for nosocomial diseases
Website:
www.gadia.net
Headquarter:
Monthey
Foundation Date:
October 2019
Technology:
- Medtech
Sectors:
- Diagnostics